<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 17:00-17:30| **Charles Sawyers** - New York, USA  
*Drug Resistance in Cancer*                                                      |
| 17:30-18:00| **Lisa Coussens** - Portland, USA  
*Neutralizing Protumor Inflammation: Lessons Learned from Preclinical Mouse Models of Cancer* |
| 18:00-18:30| **Incyte lecture: Laurence Zitvogel** - Villejuif, France  
*The intestinal microbiome in anticancer therapy*                                |
| 19:00-     | **Opening Reception**                                                    |
Day 2: Sunday September 09, 2018

Session 2:  **Immunotherapy I**  *sponsored by Roche*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 9:00-9:30 | **Novartis lecture:**  **Antoni Ribas** - Los Angeles, USA  
*Overcoming resistance to PD-1 blockade therapy* |
| 9:30-9:45 | **short talk:**  **George Coukos** - Lausanne, Switzerland  
*CCL5 is a tumor-extrinsic tumor suppressor gene, which establishes a mandatory cooperation with CXCL9 to orchestrate CD8 T-cell attack in tumors* |
| 9:45-10:15 | **Eduard Batlle** - Barcelona, Spain  
*“Immune evasion and metastasis in colorectal cancer”* |
| 10:15-10:45 |  **Coffee Break** |
| 10:45-11:00 | **short talk:**  **Victoria Pelly** - Manchester, United Kingdom  
*Cyclooxygenase-2 inhibitors and immune checkpoint blockade therapy synergistically promote tumor control* |
| 11:00-11:30 | **Karin de Visser** - Amsterdam, Netherlands  
*“The genetic makeup of primary breast tumors dictates pro-metastatic systemic inflammation”* |
| 11:30-11:45 | **Poster Speed Dating**  
5x Poster Summaries |
| 12:00-13:30 | **Lunch (+ informal poster viewing)** |

Session 3:  **Immunotherapy II**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 13:30-14:00 | **Suzanne Topalian** - San Francisco, USA  
*PD-1 blockade: a common denominator for cancer therapy* |
| 14:00-14:20 | **Novartis lecture:**  **Olivier Michielin** - Lausanne, Switzerland  
*“Protein engineering for adoptive T cell therapy”* |
| 14:20-14:35 | **short talk:**  **Michaël Cerezo** - Villejuif, France  
*The elf4F Translation Complex Controls T lymphocyte-Induced PD-L1 Expression to Mediate Tumor Immune Escape* |
| 14:35-15:05 | **Michel Sadelain** - New York, USA  
*“T cell engineering: CD19 CAR therapy and beyond”* |
| 15:05-16:30 | **POSTER SESSION 1** (+ coffee break) |

Session 4:  **Cancer Genetics**  *sponsored by Foundation ISREC*
16:30-17:00 Tyler Jacks - Cambridge, USA
"Engineering the Cancer Genome"

17:00-17:30 Scott Lowe - New York, USA
"Cancer drivers and dependencies"

17:30-18:00 Karen Cichowski - Boston, USA
"Developing therapies for Ras driven cancers"

18:00-19:15 Networking Dinner

Session 5: Metabolic Phenotypes

19:30-20:00 Lew Cantley - New York, USA
"PI 3-Kinase and Cancer Metabolism"

20:00-20:15 short talk: Viraj Sanghvi - New York, USA
Sweetening up NRF2

20:15-20:30 short talk: Subhra Biswas - Singapore, Singapore
Monocytes and macrophages undergo a metabolic re-programming in tumor settings that regulates their pro-tumor functions

20:30-21:00 Matthew Vander Heiden - Cambridge, USA
"Considerations to target metabolism for cancer therapy"

Day 3: Monday September 10, 2018

Session 6: Tumor Microenvironment

9:00-9:30 Jeffrey Pollard - Edinburgh, United Kingdom
"Macrophage Maleficence in cancer"

9:30-9:45 short talk: Arianna Calcinotto - Bellinzona, Switzerland
IL23 secreted by myeloid cells drives castration resistant prostate cancer

9:45-10:15 Sheila A. Stewart - St. Louis, USA
"Age-related stromal changes drive tumorigenesis"

10:15-10:45 Coffee Break

10:45-11:00 short talk: Simone Ragusa - Epalinges, Switzerland
Targeting the tumor microenvironment for treatment of chemoresistant desmoplastic colorectal cancer

11:00-11:15 short talk: Freddy Radtke - Lausanne, Switzerland
AMPK promotes survival of c-Myc positive melanoma cells by suppressing oxidative stress

11:15-11:45 Erik Sahai - London, USA
‘New mechanisms of tumor-stroma crosstalk and implications for therapy’

11:45-12:00 **Poster Speed Dating**  4x Poster Summaries

12:00-13:30 **Lunch (+ informal poster viewing)**

### Session 7: Epigenetics - Sponsored by Foundation ISREC

13:30-14:00 **Stephen Baylin** - Baltimore, USA  
“A critical role of epigenetic changes in the initiation and progression of most cancers? Implications for cancer prevention, interception and therapy.”

14:00-14:15 short talk: **Elisa Oricchio** - Lausanne, Switzerland  
“Structural and functional modifications of the 3D organization of the genome in EZH2 mutated tumors”

14:15-14:30 short talk: **Arthur Lambert** - Cambridge, USA  
Identifying transcriptional drivers of the cancer stem cell state

14:30-15:00 **Carlos Caldas** - Cambridge, United Kingdom  
*Breast Cancer Heterogeneity – A Systems Level View*

15:00-16:30 **POSTER SESSION 2 (+ coffee break)**

### Session 8: Complexities Modulating Tumor Phenotypes

16:30-17:00 Incyte lecture: **Drew Pardoll** - Baltimore, USA  
*Identification of gut microbiome species that promote pro-carcinogenic and anti-cancer immunity*

17:00-17:15 short talk: **Daniela Taverna** - Torino, Italy  
*miR-214 in tumor-stroma cell interactions*

17:15-17:30 short talk: **Giovanni Ciriello** - Lausanne, Switzerland  
*Cancer Evolutionary Dependencies*

17:30-18:00 **Michele De Palma** - Lausanne, Switzerland  
*Neoadjuvant chemotherapy elicits a pro-metastatic cascade through extracellular vesicles and monocytes*
## Day 4: Tuesday September 11, 2018

### Session 9: Mechanism-Guided Therapeutic Strategies & Drug Designs

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00-9:30</td>
<td><strong>Jeff Settleman</strong> - South San Francisco, USA</td>
<td></td>
<td>&quot;Reversible states of drug resistance in cancer cell subpopulations&quot;</td>
</tr>
<tr>
<td>9:30-9:45</td>
<td>short talk: <strong>Stephane Rocchi</strong> - Nice, France, Metropolitan</td>
<td></td>
<td><em>New anti-melanoma compounds targeting endoplasmic reticulum stress</em></td>
</tr>
<tr>
<td>9:45-10:15</td>
<td><strong>Guido Kroemer</strong> - Paris, France</td>
<td></td>
<td>&quot;Immunogenic stress for anticancer therapy&quot;</td>
</tr>
<tr>
<td>10:15-10:45</td>
<td><em>Coffee Break</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45-11:00</td>
<td>short talk: <strong>Li Tang</strong> - Lausanne, Switzerland</td>
<td></td>
<td><em>Development of a Responsive Cancer Nanovaccine against Neoantigens</em></td>
</tr>
<tr>
<td>11:00-11:15</td>
<td>short talk: <strong>Lluis Fajas</strong> - Lausanne, Switzerland</td>
<td></td>
<td><em>Cyclin-dependent kinase 4 (CDK4) depletion or inhibition blocks lysosomal function and inactivates the mTOR pathway in breast cancer cells and tumors in mice.</em></td>
</tr>
<tr>
<td>11:15-11:45</td>
<td><strong>Charles Swanton</strong> - London, United Kingdom</td>
<td></td>
<td><em>Cancer Evolution and Immune Escape: TRACERx</em></td>
</tr>
<tr>
<td>12:00-14:30</td>
<td><em>Lunch</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Session 10: Metastasis and Cancer Stem Cells

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30-15:00</td>
<td><strong>Christine Iacobuzio-Donahue</strong> - New York, USA</td>
<td></td>
<td>&quot;Clonal Evolution in Pancreatic Cancer&quot;</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td><strong>Jacco van Rheenen</strong> - Amsterdam, Netherlands</td>
<td></td>
<td>&quot;Intravital Microscopy reveals the dynamic nature of (cancer) stem cells during the development and homeostasis of tissues and the progression of cancer&quot;</td>
</tr>
<tr>
<td>15:30-15:45</td>
<td>short talk: <strong>Sakari Vanharanta</strong> - Cambridge, United Kingdom</td>
<td></td>
<td><em>Cross-lineage enhancer co-option as a source of metastatic traits</em></td>
</tr>
<tr>
<td>15:45-16:15</td>
<td><strong>Joan Massagué</strong> - New York, USA</td>
<td></td>
<td><em>Latency and outbreak of metastatic stem cells</em></td>
</tr>
</tbody>
</table>